Ray Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 33

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $125M

  • Investors
  • 12

Ray Therapeutics General Information

Description

Developer of optogenetic gene therapies designed to restore visual function in individuals affected by degenerative retinal diseases. The company offers a bioengineered therapeutic platform that utilizes viral vectors to deliver light-sensitive proteins to surviving retinal neurons, enabling patients with retinitis pigmentosa and other blinding conditions to regain functional vision and improve daily independence.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2607 7th Street
  • Suite B
  • Berkeley, CA 94710
  • United States
+1 (858)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 2607 7th Street
  • Suite B
  • Berkeley, CA 94710
  • United States
+1 (858)

Ray Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ray Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 21-Apr-2026 $125M Completed Clinical Trials - General
4. Grant 25-Apr-2025 Completed Clinical Trials - General
3. Early Stage VC (Series A) 15-May-2023 Completed Clinical Trials - General
2. Grant 26-Apr-2022 $4M $6M Completed Clinical Trials - General
1. Seed Round 04-Jan-2022 $6M $6M Completed Clinical Trials - General
To view Ray Therapeutics’s complete valuation and funding history, request access »

Ray Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 7,500,000 $0.000100 8% $0.8 $0.8 1x $0.8 5.04%
To view Ray Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Ray Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of optogenetic gene therapies designed to restore visual function in individuals affected by degenerative reti
Drug Discovery
Berkeley, CA
33 As of 2026

Redwood City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ray Therapeutics Competitors (1)

One of Ray Therapeutics’s competitors is Adverum Biotechnologies, a Formerly VC-backed company based in Redwood City, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adverum Biotechnologies Formerly VC-backed Redwood City, CA
You’re viewing 1 of 1 competitors. Get the full list »

Ray Therapeutics Patents

Ray Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026232050-A1 Methods and compositions to assess potency of post-transduction channelrhodopsin Pending 02-May-2025
WO-2026085387-A1 Multi-luminance mobility test for the assessment of vision Pending 18-Oct-2024
AU-2024221317-A1 Gene therapy compositions and methods for treating diseases of the retina Pending 17-Feb-2023
EP-4665750-A1 Gene therapy compositions and methods for treating diseases of the retina Pending 17-Feb-2023
US-20250387513-A1 Gene therapy compositions and methods for treating diseases of the retina Pending 17-Feb-2023 A61K48/005
To view Ray Therapeutics’s complete patent history, request access »

Ray Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ray Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adage Capital Management Hedge Fund Minority
Franklin Templeton (Asia Pacific) Asset Manager Minority
Invus (Private Equity) PE/Buyout Minority
Janus Henderson Investors Asset Manager Minority
Marshall Wace Hedge Fund Minority
You’re viewing 5 of 12 investors. Get the full list »

Ray Therapeutics FAQs

  • When was Ray Therapeutics founded?

    Ray Therapeutics was founded in 2021.

  • Where is Ray Therapeutics headquartered?

    Ray Therapeutics is headquartered in Berkeley, CA.

  • What is the size of Ray Therapeutics?

    Ray Therapeutics has 33 total employees.

  • What industry is Ray Therapeutics in?

    Ray Therapeutics’s primary industry is Drug Discovery.

  • Is Ray Therapeutics a private or public company?

    Ray Therapeutics is a Private company.

  • What is the current valuation of Ray Therapeutics?

    The current valuation of Ray Therapeutics is .

  • What is Ray Therapeutics’s current revenue?

    The current revenue for Ray Therapeutics is .

  • How much funding has Ray Therapeutics raised over time?

    Ray Therapeutics has raised $231M.

  • Who are Ray Therapeutics’s investors?

    Adage Capital Management, Franklin Templeton (Asia Pacific), Invus (Private Equity), Janus Henderson Investors, and Marshall Wace are 5 of 12 investors who have invested in Ray Therapeutics.

  • Who are Ray Therapeutics’s competitors?

    Adverum Biotechnologies is a competitor of Ray Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process